📊 PTHS Key Takeaways
Is Pelthos Therapeutics Inc. (PTHS) a Good Investment?
Pelthos is a clinical-stage biotech burning $22.6M annually in operating cash while generating only $16.8M in revenue, creating severe runway constraints. Operating margins of -193% and deteriorating net income (-444.6% YoY) indicate worsening fundamentals with ~9 months of cash runway at current burn rates. Without successful clinical advancement, meaningful revenue growth, or major cost restructuring, the company faces imminent liquidity pressure and financing dilution risk.
Why Buy Pelthos Therapeutics Inc. Stock? PTHS Key Strengths
- Zero long-term debt with 0.00x debt-to-equity ratio reduces leverage risk
- Current ratio of 2.05x provides near-term liquidity cushion for operations
- Minimal capital expenditure ($99K) demonstrates capital-efficient operating model
PTHS Stock Risks: Pelthos Therapeutics Inc. Investment Risks
- Negative operating cash flow of -$22.6M against only $18.0M cash balance creates critical runway constraint (<1 year)
- Net margin of -257.9% indicates company loses $2.58 for every $1.00 of revenue, unsustainable without dramatic business inflection
- YoY net income deterioration of -444.6% and missing gross profit data suggest pre-revenue or failed commercialization trajectory
- Rapid cash burn rate will likely force dilutive equity financing or debt issuance within 6-12 months
Key Metrics to Watch
- Quarterly burn rate trend and cash runway extension timelines
- Revenue growth trajectory and gross margin achievement from product commercialization
- Clinical trial progress and regulatory milestones that could impact valuation and financing
- Insider trading patterns and upcoming capital raises or financing announcements
Pelthos Therapeutics Inc. (PTHS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.05x current ratio provides a solid financial cushion.
PTHS Profit Margin, ROE & Profitability Analysis
PTHS vs Healthcare Sector: How Pelthos Therapeutics Inc. Compares
How Pelthos Therapeutics Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Pelthos Therapeutics Inc. Stock Overvalued? PTHS Valuation Analysis 2026
Based on fundamental analysis, Pelthos Therapeutics Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Pelthos Therapeutics Inc. Balance Sheet: PTHS Debt, Cash & Liquidity
PTHS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Pelthos Therapeutics Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-14.27 indicates the company is currently unprofitable.
PTHS Revenue Growth, EPS Growth & YoY Performance
PTHS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $294.0K | -$1.7M | $-2.93 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Pelthos Therapeutics Inc. Dividends, Buybacks & Capital Allocation
PTHS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Pelthos Therapeutics Inc. (CIK: 0001919246)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PTHS
What is the AI rating for PTHS?
Pelthos Therapeutics Inc. (PTHS) has an AI rating of STRONG SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PTHS's key strengths?
Claude: Zero long-term debt with 0.00x debt-to-equity ratio reduces leverage risk. Current ratio of 2.05x provides near-term liquidity cushion for operations.
What are the risks of investing in PTHS?
Claude: Negative operating cash flow of -$22.6M against only $18.0M cash balance creates critical runway constraint (<1 year). Net margin of -257.9% indicates company loses $2.58 for every $1.00 of revenue, unsustainable without dramatic business inflection.
What is PTHS's revenue and growth?
Pelthos Therapeutics Inc. reported revenue of $16.8M.
Does PTHS pay dividends?
Pelthos Therapeutics Inc. does not currently pay dividends.
Where can I find PTHS SEC filings?
Official SEC filings for Pelthos Therapeutics Inc. (CIK: 0001919246) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PTHS's EPS?
Pelthos Therapeutics Inc. has a diluted EPS of $-23.04.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is PTHS a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Pelthos Therapeutics Inc. has a STRONG SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is PTHS stock overvalued or undervalued?
Valuation metrics for PTHS: ROE of -111.4% (sector avg: 15%), net margin of -257.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy PTHS stock in 2026?
Our dual AI analysis gives Pelthos Therapeutics Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PTHS's free cash flow?
Pelthos Therapeutics Inc.'s operating cash flow is $-22.6M, with capital expenditures of $99.0K. FCF margin is -135.1%.
How does PTHS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -257.9% (avg: 12%), ROE -111.4% (avg: 15%), current ratio 2.05 (avg: 2).